Published online before print June 23, 2005, doi: 10.1161/01.ATV.0000175297.37214.a0
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 American Heart Association, Inc.
Atherosclerosis and Lipoproteins |
Familial Combined Hyperlipidemia in Mexicans
Association With Upstream Transcription Factor 1 and Linkage on Chromosome 16q24.1
From the Unidad de Biología (A.H.-V., S.C-Q., L.R.-R., T.T.-L.), Molecular y Medicina Genómica del Instituto de Investigaciones Biomédicas de la UNAM y del Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico City, Mexico; the Department of Human Genetics (A.H.-V., A.J.L., R.M.C., J.C.L., A.J., P.P.), David Geffen School of Medicine at UCLA, University of California, Los Angeles; and the Department of Endocrinology and Metabolism (C.A.-S., L.M.-N., R.M.), Instituto Nacional de Ciencias Medicas y Nutricion, Salvador Zubiran, Mexico City, Mexico.
Correspondence to Päivi Pajukanta, MD, PhD, Department of Human Genetics, David Geffen School of Medicine at UCLA, Gonda Center, Room 5309A, 695 Charles E. Young Drive South, Los Angeles, California 90095-7088. E-mail ppajukanta{at}mednet.ucla.edu
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Objective— To investigate the largely unknown genetic component of the common lipid disorder, familial combined hyperlipidemia (FCHL) in Mexicans, we analyzed the upstream transcription factor 1 (USF1) gene that was recently associated with FCHL and high triglycerides (TG) in Finns. We also analyzed the Mexican FCHL families for 26 microsatellite markers residing in the seven chromosomal regions on 2p25.1, 9p23, 10q11.23, 11q13, 16q24.1, 19q13, and 21q21, previously linked to FCHL in Whites.
Methods and Results— We genotyped 314 individuals in 24 Mexican families for 13 SNPs spanning an 88-kb region, including USF1. The FCHL and TG traits showed significant evidence for association with 3 SNPs, hCV1459766, rs3737787, and rs2073658, and haplotype analyses further supported these findings (probability values of 0.05 to 0.0009 for SNPs and their haplotypes). Of these SNPs, hCV1459766 is located in the F11 receptor (F11R) gene, located next to USF1, making it difficult to exclude. Importantly, the association was restricted to a considerably smaller region than in the Finns (14 kb versus 46 kb), possibly because of a different underlying linkage disequilibrium structure. In addition, 1 of the 7 regions, 16q24.1, showed suggestive evidence for linkage (a lod score of 2.6) for total cholesterol in Mexicans.
Conclusions— This study, the first to extensively investigate the genetic component of the common FCHL disorder in Mexicans, provides independent evidence for the role of USF1 in FCHL in an outbred population and links the 16q24.1 region to an FCHL-component trait in Mexicans.
To investigate the genetic component of familial combined hyperlipidemia (FCHL) in Mexican FCHL families, we analyzed the upstream transcription factor 1 (USF1) gene and 7 chromosomal loci previously identified for FCHL. In Mexicans, USF1 was associated with FCHL and triglycerides, and a locus on 16q24.1 linked to total cholesterol.
Key Words: familial combined hyperlipidemia • USF1 gene • complex traits • Mexican population • coronary heart disease
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Familial combined hyperlipidemia (FCHL) is a common heterogeneous disorder, characterized by the presence of multiple lipoprotein phenotypes that increase the risk of premature coronary heart disease (CHD).1 Families with this condition typically exhibit a mixed pattern of lipid abnormalities, with one or more family members affected by high levels of serum total cholesterol (TC) and/or triglycerides (TG). FCHL profiles are often associated with elevated apolipoprotein B (apoB) levels and with an unfavorable decrease in serum high-density lipoprotein cholesterol (HDL-C) levels.2,3 Although it has been evident for 30 years that FCHL has a strong genetic component,1 DNA sequence variants contributing to FCHL and its component traits are largely unknown, especially regarding the prevalence of variants with major effects.
Several genetic studies have been conducted in various ethnic groups to identify susceptibility genes for FCHL and its component traits.4–11 Evidence for a major FCHL locus was first found on chromosome 1q21-q23 in Finns,5 and subsequent replications were observed in US, German, Chinese, and Dutch populations.9–11 Linkage to the 1q21–23 region has also been replicated in 7 extended Mexican families.12 These 7 families comprise a portion of the samples investigated in this present study. Recently, Pajukanta et al (2004)13 reported that FCHL is linked and associated with the gene encoding the upstream transcription factor 1 (USF1) on chromosome 1q21. USF1 is the first major gene implicated in FCHL.
The ubiquitously expressed USF proteins are members of the basic helix-loop-helix leucine zipper (bHLH-zip) family of transcription factors, and USF1 is known to control expression of several genes involved in glucose and lipid metabolism.14,15 Variation in USF1 has been shown to influence features of glucose and lipid homeostasis in the EARS II offspring study.16 Recently USF1 was also shown to stimulate apolipoprotein A-V (APOA5) promoter activity in an insulin-dependent manner, demonstrated by the reduced binding of USF1 to the APOA5 promoter in the presence of insulin.17 This connection between APOA5 and USF1 is especially noteworthy because variants of APOA5 have been linked to high TGs in both the general population18 and in FCHL.19–21 However, additional studies are warranted to replicate the role of USF1 in FCHL families originating from other populations than the genetically homogeneous Finns to confirm that USF1 alleles truly have relevance for FCHL. In the present study, we investigated the USF1 gene on 1q21 in the more outbred population of Mexico. Previous studies have clearly demonstrated that the Mexican population has an increased predisposition to mixed dyslipidemias, including FCHL.22–24 However, this population has been under-investigated for the genetic factors conferring this susceptibility.
It is likely that alleles of multiple genes contribute to the complex FCHL phenotype. In fact, genome-wide scans have identified several chromosomal loci for FCHL and its component traits in Caucasian families with FCHL.6–8,25,26 Loci on chromosomes 1q21, 2q31, 10p11, 10q11, 16q, and 21q21 were identified in the Finnish FCHL families;5–6,26 loci on chromosomes 2p, 11p, 16q, and 19q in the Dutch FCHL families;7,8 and loci on 6q, 8p, and 11p in the British FCHL families,25 respectively. Therefore, we also analyzed the Mexican FCHL families for peak markers of 7 regions identified in the previous genome scans of Caucasian FCHL families.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Subjects and Clinical Features
A total of 24 extended Mexican FCHL families with a history of premature CHD were included in this study, comprising 314 family members (Table 1a and 1b
). These families were recruited in the Lipid Clinic of the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ) in Mexico City. The ethnicity and race of these subjects reflect the general population of Mexico. Thus, the race of all of these subjects is Mestizos who are a mixture of American Indian and white. Inclusion criteria for the probands were as follows: Elevated levels of serum TGs (
the 90th age/sex-specific Mexican population percentile) and/or elevated levels of serum TC (the 90th percentile) and elevated levels of serum apoB (the 90th percentile). The positive family history of premature CHD before the age of 60 years was defined as the manifestation of myocardial infarction either in the proband or a first-degree relative of the proband. The age/sex-specific population percentiles for lipids were based on a previous survey of the Mexican population.23 In addition, at least 1 first-degree relative had a phenotype of high TC (the 90th percentile) or high TGs (the 90th percentile) different from that of the proband. Exclusion criteria for the probands were tendon xanthomas, renal disease, and thyroid disorders. All subjects completed a questionnaire about their medical history, medication, as well as smoking and drinking habits. Body mass index (BMI) was determined for all subjects. Each subject provided a written informed consent. The protocol for this study was approved by the Institutional Committee of Biomedical Research in Humans of the INCMNSZ.
|
|
Laboratory Analytical Methods
All lipid levels for affected individuals were measured before treatment. The measurements were performed with commercially available standardized methods. Glucose was measured using the glucose oxidase method; serum TC and TGs were measured using an enzymatic method (SERA-PAK®); HDL-C levels were assessed using phosphotungstic acid and Mg2+; LDL-C concentrations were estimated by the Friedewald formula,27 and plasma apoB measurements were obtained using a commercially available assay (Beckman).
Genotyping
We genotyped 314 individuals from the 24 families for 13 SNPs, spanning USF1 and the 2 genes flanking USF1, F11 receptor (F11R), and a hypothetical gene LOC257106. Eight of these SNPs were reported previously.13 Five additional SNPs (rs1023115, rs1240334, rs2481084, rs2774279, and rs3813610) were selected from the dbSNP database. The SNPs were genotyped using the pyrosequencing technique on the automated PSQ HS96A platform. We genotyped 26 peak microsatellite markers for the previously linked regions on 2p25.1, 9p23, 10q11.23, 11q13, 16q24.1, 19q13, and 21q21,6–8,26 using the ABI Prism 3700 DNA Analyzer and the Genotyper 3.7 software.
Statistical Analysis
Because of the acknowledged difficulties to replicate results obtained in genetic analyses of complex traits, we used the same diagnostic criteria, the same methods, and the same markers as described previously with the USF1 gene and Dutch and Finnish genome scans.5–7,13,26 Accordingly,13 we tested the SNPs for association using the haplotype-based haplotype risk (HHRR),28 family-based association (FBAT),29 and gamete competition30 tests. The HHRR tests the homogeneity of marker allele distributions between transmitted and nontransmitted alleles, extracting information also from homozygous parents. The FBAT option –o assesses not only preferential transmission of susceptibility haplotypes to affecteds but also less preferential transmissions to unaffecteds, capturing additional information in these extended Mexican families. The FBAT (and HBAT for haplotypes) option –e leads to a test of association given linkage and thus allows for the association analysis of multiple affected individuals in the presence of linkage. The HBAT option –e was used for the haplotype analysis of the SNPs. Although the FBAT –e (and HBAT –e) allows assessment of association given linkage, the pedigrees are trimmed to nuclear families and only a subset of the data are used, reducing power. Therefore, the gamete competition test that makes effective use of full pedigree data was applied. It is, however, not a test of pure association because it has the null hypothesis of no association and no linkage, and thus, linkage to the tested locus contributes to the observed probability value.
Two traits, high TG and FCHL, associated in the previous study13 were tested. The affection status for these traits was defined using the 90th Mexican age/sex-specific population percentiles of TC and TGs (the FCHL trait) and the 90th age/sex-specific percentiles of TGs (the high TG trait). The extent of pairwise linkage disequilibrium (LD) between the marker genotypes was tested using the JLIN: JAVA LD PLOTTER program available online (http://www.genepi.com.au/project/jlin).
For linkage analysis of microsatellite markers, we carried out the same parametric and nonparametric 2-point analyses as were used previously5–7,13,26 with the MLINK program of the LINKAGE package and the SIBPAIR program, as implemented in the ANALYZE package.31 We assumed a disease allele frequency of 0.006 under the dominant mode of inheritance and 0.1095 under the recessive mode of inheritance.5–7,13,26 Linkage analyses of the microsatellite markers were performed for the dichotomized FCHL, TG, TC, and low HDL-C traits, as described previously.5–7,26 Allele frequencies were estimated from all individuals using the DOWNFREQ program.32 The PedCheck program was used to assess the genotype data for pedigree inconsistencies.33 The multipoint analyses for 16q24.1 and 10q11.23 were performed using the GENEHUNTER program.34
Statistical Significance
We performed 2 classes of analyses. In the study of USF1, two traits were tested for association with 13 SNPs. The Bonferroni correction for the probability values obtained in these analyses can be considered overly conservative, because we investigate highly correlated SNPs and traits. We are conducting the same analyses seen in Pajukanta et al13 and are examining the results in aggregate to see if a similar pattern of linkage and association is observed in the Mexican FCHL families. Thus, we are expecting significant evidence of linkage and association with additional evidence of just association for the 6 previously associated SNPs. An additional 7 SNPs were genotyped to help restrict the associated region. Thus, in these analyses, we are reporting a probability value of 0.05 or less. In the linkage study, 7 previously identified chromosomal regions were tested for linkage with 4 correlated traits. When evaluating these linkage results, we used the previous guidelines for suggestive and significant evidence of linkage.35
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
To investigate the underlying genetic component for FCHL within the USF1 region in the Mexican population, we genotyped a total of 13 SNPs spanning an 88-kb region, including three genes, USF1, F11 receptor (F11R), and hypothetical gene LOC257106 (Table 2a). The F11R and hypothetical gene LOC257106 were investigated besides USF1 in Mexicans, because in Finns the associated region extended to an
46-kb region that also covered the F11R gene, specifically in TG-affected Finnish males.13
|
|
One F11R SNP, hCV1459766, and 2 USF1 SNPs, rs3737787 and rs2073658, within a 14-kb region, showed evidence for association with the FCHL and TG traits (Table 2a and 2b
). Specifically, the TG trait produced the most significant signal for association, resulting in probability values of 0.001, 0.005, and 0.001 for SNPs hCV1459766, rs3737787, and rs2073658, respectively, when testing for linkage and association in nuclear families using the FBAT option –o (Table 2a). When testing for association and accounting for linkage using the FBAT option –e, the SNPs hCV1459766 and rs3737787 resulted in probability values of 0.04 and 0.02 (Table 2a). These results are in accordance with the results obtained when testing for linkage and association in the extended families using the gamete competition test (Table 2a). Moreover, haplotype analysis for SNPs hCV1459766-rs3737787 provided evidence of association with both traits, TGs (P=0.0009) and FCHL (P=0.02) using the HBAT option –e (Table 2b). Although these 3 SNPs are in strong LD with one another, their pairwise r2 measurements of 0.86 for SNPs hCV1459766 and rs3737787 in probands compared with 0.64 in spouses appears to allow for the additional evidence of association obtained by haplotype analysis. The pairwise r2 measurement for SNPs rs3737787 and rs2073658 was 1.0 in probands and 0.73 in spouses. Interestingly, LD between the SNPs hCV1459766, rs3737787, and rs2073658 appeared thus to be tighter in probands than in spouses. The Figure shows the locations of the 13 SNPs and the pairwise LD between them separately in spouses and probands. As in the Finns,13 the preferentially transmitted alleles of these SNPs and their haplotypes were the major alleles (Table 2b). The haplotype of the minor alleles in turn was significantly less transmitted to the affected individuals (P=0.001 for TGs and P=0.02 for FCHL) (Table 2b). None of the other SNPs produced significant probability values. The nucleotides for minor alleles in Mexicans are shown in Supplementary Table I (available at the web site, http://www.genetics.ucla.edu/labs/pajukanta/fchlmex/).
|
The pedigree structure and phenotypic characteristics of the Mexican families used in the full pedigree linkage analyses are shown in Tables 1a and 1b. In 2-point linkage analyses of the 7 regions previously linked to FCHL and its component traits,6–8,26 we obtained maximum lod scores of 1.8 for chromosome 10q11.23 with marker D10S1772 for TGs and 2.6 for chromosome 16q24.1 with marker D16S505 for TC (Table 3). We also analyzed these 2 regions in a multipoint analysis using the GENEHUNTER software. For chromosome 16q24.1, an NPL score of 2.2 was obtained, whereas for 10q11.23, an NPL score of 0.6 was observed. Thus, no additional support was obtained for chromosome 10q11.23 in the multipoint analysis. No lod scores over 2.0 were observed for TG, FCHL, or low HDL-C in any of the investigated regions, nor for TC in the 6 remaining regions. Linkage results for all analyzed regions with the FCHL and its component traits are shown in Supplementary Table II (available at the web site, http://www.genetics.ucla.edu/labs/pajukanta/fchlmex/).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Our results taken in aggregate provide evidence that variants in USF1 are associated with FCHL and TGs in Mexican FCHL families. The SNPs hCV1459766, rs3737787, and rs2073658 showed significant evidence for association with both traits. As in the original study,13 the most significant association was observed with the high TG trait. Furthermore, haplotype analysis for SNPs hCV1459766-rs3737787 showed significant evidence for association with both traits, TGs (P=0.0009) and FCHL (P=0.02). As in the Finns,13 the major alleles and haplotypes formed by the major alleles were associated with FCHL and TGs. Similarly, the transmission of the haplotype of minor alleles to the affected individuals was reduced. However, there were differences in these results when compared with the Finns,13 possibly because of a different underlying LD structure. First, the most significant evidence for association was observed with the haplotypes of the SNPs hCV1459766-rs3737787 (versus the SNPs rs3737787-rs2073658 in Finns). Second, the association was restricted to a 14-kb region in the Mexican families with FCHL when compared with the 46-kb in the TG-affected Finnish males.13 Third, in contrast to these Finnish results that showed extension of the associated region specifically in TG affected males, no sex-specific effects were observed in the Mexican families. Although we cannot exclude the possibility that the relatively small sample size of this Mexican study contributes to these results, the observed results suggest that the FCHL/TG-associated region can be restricted to 14 kb between intron 7 of USF1 (rs2073658) and intron 1 of F11R (hCV1459766). Thus the association evidence extends to F11R with the FCHL and TG traits, and we cannot genetically exclude F11R as an underlying gene for FCHL. However, the known functions of F11R, mainly associated with T-cell migration and epithelial tight junction formation,36 make it a substantially less likely candidate for FCHL than USF1.
None of the associated SNPs in the Finns or Mexicans result in an amino acid change, and in sequence analyses of the Finnish probands, no missense or nonsense variants were identified in USF1.13 Therefore, restriction of the associated region by 70% in these Mexican families makes the possibility for functional analysis of these variants considerably more feasible because a shorter region with fewer variants is now available for these analyses. This conclusion is also supported by the differences we observed in the LD structure between probands and spouses in the Mexican families.
In spite of the compelling evidence for the replication of the original association in the Mexican population, it is important to emphasize the need to sequence the USF1 and F11R genes in the Mexicans in future studies. We could fail to detect additional, possibly even coding variants that are associated in the Mexican population, as well as important differences in LD structure and allelic heterogeneity. Therefore, a gene-based approach that considers all common variations within a gene jointly is needed to resolve the possible inconsistencies arising from population differences.37
Here we also report a region on chromosome 16q24.1 to show suggestive evidence for linkage with TC in the Mexican families. Previous data from a combined analysis of the Dutch and Finnish genome-wide scans for FCHL provided evidence that the 16q24.1 region is linked to low HDL-C,7 producing a parametric multipoint LOD score of 3.6 for the low HDL-C trait. Importantly, this region on 16q24.1 has also been linked to HDL-C in an independent study of Mexican Americans.38 In the combined analysis of the Dutch and Finnish FCHL families,7 the maximum 2-point LOD score of 2.0 was obtained with marker D16S505 for low HDL-C; whereas for TC, the adjacent marker D16S3091 (2.1 cM apart) produced the highest 2-point LOD score of 1.6. Interestingly, the TC trait produced the highest evidence for linkage in the Mexican FCHL families, resulting in a 2-point ASP LOD score of 2.6 with marker D16S505 and a multipoint NPL score of 2.2. Although the maximum LOD scores for this region on 16q24.1 were observed for different traits in the Mexicans than in the Finns and Dutch, we assume that the complexity of the genetic and environmental processes that regulate the expression of the complex FCHL phenotypes in each population contributes to this difference.
Several studies have demonstrated that the Mexican population has a high genetic predisposition to the type 2 diabetes mellitus, metabolic syndrome, and some primary forms of dyslipidemias.22–24 In Mexicans, at age 50, 27.6% of men and 21% of women exhibit mixed dyslipidemia.23 These data suggest that the most common causes of mixed dyslipidemias, such as type 2 diabetes mellitus and FCHL, are common abnormalities in the Mexican population. Therefore, it is critical to identify genetic variants that confer susceptibility to high serum lipid levels in this population. The present study is the first report to extensively investigate the genetic component of the common FCHL disorder in the Mexican population.
|
Acknowledgments |
|---|
This research was supported by the UC-MEXUS CONACYT grant, National Institutes of Health grants HL-28481 and HL-70150, as well as American Heart Association grant 0430180N. A.H.V. received support through CONACyT fellowship. We thank the family members for participating in this study. We thank S. Ramirez and M. Rodriguez for technical support.
Received February 25, 2005; accepted June 6, 2005.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
- Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest. 1973; 52: 1544–1568.
- Brunzell JD, Albers JJ, Chait A, Grundy SM, Groszek E, McDonald GB. Plasma lipoproteins in familial combined hyperlipidemia and monogenic familial hypertriglyceridemia. J Lipid Res. 1983; 24: 147–155.[Abstract]
- Soro A, Jauhiainen M, Ehnholm C, Taskinen. Determinants of low HDL levels in familial combined hyperlipidemia. J Lipid Res. 2003;44:1536–1544.
- Wojciechowski AP, Farrall M, Cullen P, Wilson TM, Bayliss JD, Farren B, Griffin BA, Caslake MJ, Packard CJ, Shepherd J. Familial combined hyperlipidaemia linked to the apolipoprotein AI-CII-AIV gene cluster on chromosome 11q23–q24. Nature. 1991; 349: 161–164.[CrossRef][Medline] [Order article via Infotrieve]
- Pajukanta P, Nuotio I, Terwilliger JD, Porkka KV, Ylitalo K, Pihlajamaki J, Suomalainen AJ, Syvanen AC, Lehtimaki T, Viikari JS, Laakso M, Taskinen MR, Ehnholm C, Peltonen L. Linkage of familial combined hyperlipidemia to chromosome 1q21–q23. Nat Genet. 1998; 18: 369–373.[CrossRef][Medline] [Order article via Infotrieve]
- Pajukanta P, Terwilliger JD, Perola M, Hiekkalinna T, Nuotio I, Ellonen P, Parkkonen M, Hartiala J, Ylitalo K, Pihlajamaki J, Porkka K, Laakso M, Viikari J, Ehnholm C, Taskinen MR, Peltonen L. Genomewide scan for familial combined hyperlipidemia genes in Finnish families, suggesting multiple susceptibility loci influencing triglyceride, cholesterol and apolipoprotein B levels. Am J Hum Genet. 1999; 64: 1453–1463.[CrossRef][Medline] [Order article via Infotrieve]
- Pajukanta P, Allayee H, Krass KL, Kuraishy A, Soro A, Lilja HE, Mar R, Taskinen MR, Nuotio I, Laakso M, Rotter JI, de Bruin TW, Cantor RM, Lusis AJ, Peltonen L. Combined analysis of genome scans of dutch and finnish families reveals a susceptibility locus for high-density lipoprotein cholesterol on chromosome 16q. Am J Hum Genet. 2003; 72: 903–917.[CrossRef][Medline] [Order article via Infotrieve]
- Aouizerat BE, Allayee H, Cantor RM, Davis RC, Lanning CD, Wen PZ, Dallinga-Thie GM, de Bruin TWA, Rotter JI, Lusis AJ. A genome scan for familial combined hyperlipidemia reveals evidence of linkage with a locus on chromosome 11. Am J Hum Genet. 1999; 65: 397–412.[CrossRef][Medline] [Order article via Infotrieve]
- Coon H, Myers RH, Borecki IB, Arnett DK, Hunt SC, Province MA, Djousse L, Leppert MF. Replication of linkage of familial combined hyperlipidemia to chromosome 1q with additional heterogeneous effect of apolipoprotein A-I/C-III/A-IV locus: the NHLBI Family Heart Study. Arterioscler Thromb Vasc Biol. 2000; 20: 2275–2280.
[Abstract/Free Full Text] - Pei W, Baron H, Muller-Myhsok B, Knoblauch H, Al-Yahyaee SA, Hui R, Wu X, Liu L, Busjahn A, Luft FC, Schuster H. Support for linkage of familial combined hyperlipidemia to chromosome 1q21–q23 in Chinese and German families. Clin Genet. 2000; 57: 29–34.[CrossRef][Medline] [Order article via Infotrieve]
- Allayee H, Krass KL, Pajukanta P, Cantor RM, van der Kallen CJ, Mar R, Rotter JI, de Bruin TW, Peltonen L, Lusis AJ. Locus for elevated apolipoprotein B levels on chromosome 1p31 in families with familial combined hyperlipidemia. Circ Res. 2002; 90: 926–931.
[Abstract/Free Full Text] - Huertas-Vazquez A, Del Rincon JP, Canizales-Quinteros S, Riba L, Vega-Hernandez G, Ramirez-Jimenez S, Auron-Gomez M, Gomez-Perez FJ, Aguilar-Salinas CA, Tusie-Luna MT. Contribution of Chromosome 1q21–q23 to Familial Combined Hyperlipidemia in Mexican Families. Ann Hum Genet. 2004; 68: 419–427.[CrossRef][Medline] [Order article via Infotrieve]
- Pajukanta P, Lilja HE, Sinsheimer JS, Cantor RM, Lusis AJ, Gentile M, Duan XJ, Soro-Paavonen A, Naukkarinen J, Saarela J, Laakso M, Ehnholm C, Taskinen MR, Peltonen L. Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1). Nat Genet. 2004; 36: 371–376.[CrossRef][Medline] [Order article via Infotrieve]
- Casado M, Vallet VS, Kahn A, Vaulont S. Essential role in vivo of upstream stimulatory factors for a normal dietary response of the fatty acid synthase gene in the liver. J Biol Chem. 1999; 274: 2009–2013.
[Abstract/Free Full Text] - Vallet VS, Casado M, Henrion AA, Bucchini D, Raymondjean M, Kahn A, Vaulont S. Differential roles of upstream stimulatory factors 1 and 2 in the transcriptional response of liver genes to glucose. J Biol Chem. 1998; 273: 20175–20179.
[Abstract/Free Full Text] - Putt W, Palmen J, Nicaud V, Tregouet DA, Tahri-Daizadeh N, Flavell DM, Humphries SE, Talmud PJ; EARSII group. Variation in USF1 shows haplotype effects, gene: gene and gene: environment associations with glucose and lipid parameters in the European Atherosclerosis Research Study II. Hum Mol Genet. 2004; 13: 1587–1597.
[Abstract/Free Full Text] - Nowak M, Helleboid-Chapman A, Jakel H, Martin G, Duran-Sandoval D, Staels B, Rubin EM, Pennacchio LA, Taskinen MR, Fruchart-Najib J, Fruchart JC. Insulin-mediated down-regulation of apolipoprotein a5 gene expression through the phosphatidylinositol 3-kinase pathway: role of upstream stimulatory factor. Mol Cell Biol. 2005; 25: 1537–1548.
[Abstract/Free Full Text] - Pennacchio LA, Olivier M, Hubacek JA, Cohen JC, Cox DR, Fruchart JC, Krauss RM, Rubin EM. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science. 2001; 294: 169–173.
[Abstract/Free Full Text] - Eichenbaum-Voline S, Olivier M, Jones EL, Naoumova RP, Jones B, Gau B, Patel HN, Seed M, Betteridge DJ, Galton DJ, Rubin EM, Scott J, Shoulders CC, Pennacchio LA. Linkage and association between distinct variants of the APOA1/C3/A4/A5 gene cluster and familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 2004; 24: 167–174.
[Abstract/Free Full Text] - Mar R, Pajukanta P, Allayee H, Groenendijk M, Dallinga-Thie G, Krauss RM, Sinsheimer JS, Cantor RM, de Bruin TW, Lusis AJ. Association of the APOLIPOPROTEIN A1/C3/A4/A5 gene cluster with triglyceride levels and LDL particle size in familial combined hyperlipidemia. Circ Res. 2004; 94: 993–999.
[Abstract/Free Full Text] - Ribalta J, Figuera L, Fernández-Ballart J, Vilella E, Castro Cabezas M, Masana L, Joven J, Newly identified apolipoprotein av gene predisposes to high plasma triglycerides in familial combined hyperlipidemia. Clinical Chemistry. 2002; 48: 1597–1600.
[Free Full Text] - Stern MP, Knapp JA, Hazuda HP, Haffner SM, Patterson JK, Mitchell BD. Genetic and environmental determinants of type II diabetes in Mexican Americans. Is there a "descending limb" to the modernization/diabetes relationship? Diabetes Care. 1991; 14: 649–654.[Abstract]
- Aguilar-Salinas CA, Olaiz G, Valles V, Torres JM, Gomez Perez FJ, Rull JA, Rojas R, Franco A, Sepulveda J. High prevalence of low HDL cholesterol concentrations and mixed hyperlipidemia in a Mexican nationwide survey. J Lipid Res. 2001; 42: 1298–1307.
[Abstract/Free Full Text] - Aguilar-Salinas CA, Velazquez Monroy O, Gomez-Perez FJ, Gonzalez Chavez A, Esqueda AL, Molina Cuevas V, Rull-Rodrigo JA, Tapia Conyer R. Encuesta Nacional de Salud 2000 Group characteristics of patients with type 2 diabetes in Mexico: results from a large population-based nationwide survey. Diabetes Care. 2003; 26: 2021–2026.
[Abstract/Free Full Text] - Naoumova RP, Bonney SA, Eichenbaum-Voline S, Patel HN, Jones B, Jones EL, Amey J, Colilla S, Neuwirth CK, Allotey R, Seed M, Betteridge DJ, Galton DJ, Cox NJ, Bell GI, Scott J, Shoulders CC. Confirmed locus on chromosome 11p and candidate loci on 6q and 8p for the triglyceride and cholesterol traits of combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 2003; 23: 2070–2077.
[Abstract/Free Full Text] - Soro A, Pajukanta P, Lilja HE, Ylitalo K, Hiekkalinna T, Perola M, Cantor RM, Viikari JS, Taskinen MR, Peltonen L. Genome scans provide evidence for low-HDL-C loci on chromosomes 8q23, 16q24.1–24.2, and 20q13.11 in Finnish families. Am J Hum Genet. 2002; 70: 1333–1340.[CrossRef][Medline] [Order article via Infotrieve]
- Friedewald WT, Levy IR, Fredrickson DS. Estimation of the concentration of low density lipoproteins cholesterol in plasma without the use of the ultracentrifuge. Clin Chem. 1972; 18: 449–502.[Abstract]
- Terwilliger JD, Ott J. A haplotype-based ‘haplotype relative risk’ approach to detecting allelic associations. Hum Hered. 1992; 42: 337–346.[CrossRef][Medline] [Order article via Infotrieve]
- Laird NM, Horvath S, Xu X. Implementing a unified approach to family-based tests of association. Genet Epidemiol. 2000; 19: S36–S42.
- Sinsheimer JS, Blangero J, Lange K. Gamete competition models. Am J Hum Genet. 2000; 66: 1168–1172.[CrossRef][Medline] [Order article via Infotrieve]
- Göring HH, Terwilliger JD. Gene mapping in the 20th and 21st centuries: statistical methods, data analysis, and experimental design. Hum Biol. 2000; 72: 63–132.[Medline] [Order article via Infotrieve]
- Göring HH, Terwilliger JD. Linkage analysis in the presence of errors III: marker loci and their map as nuisance parameters. Am J Hum Genet. 2000; 66: 1298–1309.[CrossRef][Medline] [Order article via Infotrieve]
- O’Connell JR, Weeks DE. PedCheck: a program for identification of genotype incompatibilities in linkage analysis. Am J Hum Genet. 1998; 63: 259–266.[CrossRef][Medline] [Order article via Infotrieve]
- Kruglyak L, Daly MJ, Reeve-Daly MP, Lander ES. Related Articles, Links Parametric and nonparametric linkage analysis: a unified multipoint approach. Am J Hum Genet. 1996; 58: 1347–1363.[Medline] [Order article via Infotrieve]
- Lander E, Kruglyak L. Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. Nat Genet. 1995; 11: 241–247.[CrossRef][Medline] [Order article via Infotrieve]
- Ostermann G, Weber KS, Zernecke A, Schroder A, Weber C. JAM-1 is a ligand of the ß2 integrin LFA-1 involved in transendothelial migration of leukocytes. Nat Immunol. 2002; 3: 151–158.[CrossRef][Medline] [Order article via Infotrieve]
- Neale BM, Sham PC. The future of association studies: gene-based analysis and replication. Am J Hum Genet. 2004; 75: 353–362.[CrossRef][Medline] [Order article via Infotrieve]
- Mahaney MC, Almasy L, Rainwater DL, VandeBerg JL, Cole SA, Hixson JE, Blangero J, MacCluer JW. A quantitative trait locus on chromosome 16q influences variation in plasma HDL-C levels in Mexican Americans. Arterioscler Thromb Vasc Biol. 2003; 23: 339–345.
[Abstract/Free Full Text]
This article has been cited by other articles:
 |
|
 |
|
  K. Kristiansson, E. Ilveskoski, T. Lehtimaki, L. Peltonen, M. Perola, and P. J. Karhunen Association Analysis of Allelic Variants of USF1 in Coronary Atherosclerosis Arterioscler. Thromb. Vasc. Biol., May 1, 2008; 28(5): 983 - 989. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Rada-Iglesias, A. Ameur, P. Kapranov, S. Enroth, J. Komorowski, T. R. Gingeras, and C. Wadelius Whole-genome maps of USF1 and USF2 binding and histone H3 acetylation reveal new aspects of promoter structure and candidate genes for common human disorders Genome Res., March 1, 2008; 18(3): 380 - 392. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Garg and V. Simha Update on Dyslipidemia J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1581 - 1589. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Nohara, M.-a. Kawashiri, T. Claudel, M. Mizuno, M. Tsuchida, M. Takata, S. Katsuda, K. Miwa, A. Inazu, F. Kuipers, et al. High Frequency of a Retinoid X Receptor {gamma} Gene Variant in Familial Combined Hyperlipidemia That Associates With Atherogenic Dyslipidemia Arterioscler. Thromb. Vasc. Biol., April 1, 2007; 27(4): 923 - 928. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. van der Vleuten, A. Isaacs, A. Hijmans, C. M. van Duijn, A. F. H. Stalenhoef, and J. de Graaf The involvement of upstream stimulatory factor 1 in Dutch patients with familial combined hyperlipidemia J. Lipid Res., January 1, 2007; 48(1): 193 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. G. J. Brouwers, R. M. Cantor, N. Kono, J. l. Yoon, C. J. H. van der Kallen, M. A. L. Bilderbeek-Beckers, M. M. J. van Greevenbroek, A. J. Lusis, and T. W. A. de Bruin Heritability and genetic loci of fatty liver in familial combined hyperlipidemia J. Lipid Res., December 1, 2006; 47(12): 2799 - 2807. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Reue and L. Vergnes Thematic review series: Systems Biology Approaches to Metabolic and Cardiovascular Disorders. Approaches to lipid metabolism gene identification and characterization in the postgenomic era J. Lipid Res., September 1, 2006; 47(9): 1891 - 1907. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Weissglas-Volkov, A. Huertas-Vazquez, E. Suviolahti, J. Lee, C. Plaisier, S. Canizales-Quinteros, T. Tusie-Luna, C. Aguilar-Salinas, M.-R. Taskinen, and P. Pajukanta Common Hepatic Nuclear Factor-4{alpha} Variants Are Associated With High Serum Lipid Levels and the Metabolic Syndrome. Diabetes, July 1, 2006; 55(7): 1970 - 1977. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Marcil, H. Vu, W. Cui, Z. Dastani, J. C. Engert, D. Gaudet, M. Castro-Cabezas, A. D. Sniderman, J. Genest Jr, and K. Cianflone Identification of a Novel C5L2 Variant (S323I) in a French Canadian Family With Familial Combined Hyperlipemia Arterioscler. Thromb. Vasc. Biol., July 1, 2006; 26(7): 1619 - 1625. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Peltonen, M. Perola, J. Naukkarinen, and A. Palotie Lessons from studying monogenic disease for common disease. Hum. Mol. Genet., April 15, 2006; 15(suppl_1): R67 - R74. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||